Calculating Returns-on-Patent Litigation Expenditures

Other lucrative patent assertion efforts include:

• •$200 million award to USAA against Wells Fargo (later increased by $100 million for willful infringement)
• •$752 million award to Sloan Kettering against Kite Pharma
• •$500 million award to VirnetX against Apple (confirmed in 2020)
• •$400 million award to KAIST against Samsung (later settled for $200 million)
• •$506 million award to the University of Wisconsin against Apple (later overturned)
• •$155 million award to Bayer Healthcare against Baxalta Inc.
• •$137 million award to Roche Diagnostics against Meso Corp

If you believe large companies are infringing your patents, should you assert them?
While the lure of generous damages awards is tempting, patent litigation is extraordinarily
expensive and the odds of winning are far from certain.

This webinar explains how Monte Carlo Analysis can be used to determine
returns on initial patent litigation expenditures by running dozens of variables across
1,000 modeled scenarios.

The modeling forecasts thousands of possible outcomes — from receiving an unsolicited
offer in year one, to achieving treble damages in year seven, to settling pre-judgment,
or even paying the defendant’s attorneys’ fees.

The analysis clearly lays out minimum, maximum, average, and median net present values,
average return on initial investment, and the number of scenarios in which returns exceed
initial costs by at least ten times.

Course Leader

David Wanetick, CEO, IncreMental Advantage

David Wanetick has valued thousands of patents for Fortune 100 companies, startups,
universities, national laboratories, and hedge funds. He is a Managing Director at
JD Merit, developed the Certified Patent Valuation Analyst (CPVA) designation, and
is the author of seven books on patent valuation, negotiation, and innovation strategy.

Course Length

Approx. 0.75 hours

Pricing

$50.00 per user